Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

liver transplant
carcinoma
hepatocellular carcinoma
  • 0 views
  • 07 Jan, 2022
  • 1 location
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort

  • 0 views
  • 13 May, 2021
  • 1 location
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable Locally Advanced Liver Cancer

This phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating

  • 0 views
  • 20 Aug, 2021
  • 1 location
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

This Phase I, multicenter, study is designed to evaluate the safety and tolerability of durvalumab (anti-programmed death-ligand 1 [PD-L1] antibody) and tremelimumab (anti-cytotoxic T-lymphocyte

extensive stage small cell lung cancer
metastasis
etoposide
cancer chemotherapy
brain metastases
  • 0 views
  • 18 Oct, 2021
  • 1 location
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or olaparib

hepatitis b core antibody
olaparib
etoposide
pd-l1
carboplatin
  • 9 views
  • 13 May, 2022
  • 1 location
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects

platelet count
solid neoplasm
metastasis
liver metastasis
primary cancer
  • 54 views
  • 13 May, 2022
  • 1 location
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC)

features. The hypothesis is that the combination of durvalumab/MEDI4736 and tremelimumab (doublet immunotherapy) with platinum-based chemotherapy (gemcitabine and cisplatin) will yield an objective of 52

platelet count
serum bilirubin
cancer
gemcitabine
neutrophil count
  • 0 views
  • 03 May, 2022
  • 1 location
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment …

colorectal adenocarcinoma
durvalumab
adenocarcinoma
EGFR
adenocarcinoma of the gastroesophageal junction
  • 67 views
  • 30 May, 2022
  • 1 location
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)

This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.

  • 0 views
  • 05 Jun, 2022
  • 1 location
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has

durvalumab
tumor cells
selumetinib
glomerular filtration rate
tremelimumab
  • 8 views
  • 06 Feb, 2022
  • 1 location